Molecular Partners Stock Forward View - Relative Strength Index
| MOLN Stock | USD 4.61 0.21 4.77% |
Molecular Stock outlook is based on your current time horizon. Although Molecular Partners' naive historical forecasting may sometimes provide an important future outlook for the firm, we suggest always cross-verifying it against solid analysis of Molecular Partners' systematic risk associated with finding meaningful patterns of Molecular Partners fundamentals over time.
As of today the rsi of Molecular Partners' share price is below 20 . This indicates that the stock is significantly oversold. The fundamental principle of the Relative Strength Index (RSI) is to quantify the velocity at which market participants are driving the price of a financial instrument upwards or downwards. Momentum 0
Sell Peaked
Oversold | Overbought |
EPS Estimate Next Quarter (0.34) | EPS Estimate Current Year (1.53) | EPS Estimate Next Year (1.04) | Wall Street Target Price 11.9348 | EPS Estimate Current Quarter (0.37) |
Using Molecular Partners hype-based prediction, you can estimate the value of Molecular Partners AG from the perspective of Molecular Partners response to recently generated media hype and the effects of current headlines on its competitors.
Molecular Relative Strength Index
Molecular Partners Hype to Price Pattern
Investor biases related to Molecular Partners' public news can be used to forecast risks associated with an investment in Molecular. The trend in average sentiment can be used to explain how an investor holding Molecular can time the market purely based on public headlines and social activities around Molecular Partners AG. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Molecular Partners' market sentiment to its price can help taders to make decisions based on the overall investors consensus about Molecular Partners.
Molecular Partners after-hype prediction price | USD 4.4 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Molecular | Build AI portfolio with Molecular Stock |
Molecular Partners Additional Predictive Modules
Most predictive techniques to examine Molecular price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Molecular using various technical indicators. When you analyze Molecular charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Check Molecular Partners Volatility | Backtest Molecular Partners | Information Ratio |
Molecular Partners Trading Date Momentum
| On February 05 2026 Molecular Partners AG was traded for 4.61 at the closing time. The top price for the day was 4.75 and the lowest listed price was 4.40 . The trading volume for the day was 11.1 K. The trading history from February 5, 2026 did not cause price change. The trading delta at closing time against the current closing price is 2.60% . |
| Compare Molecular Partners to competition |
Other Forecasting Options for Molecular Partners
For every potential investor in Molecular, whether a beginner or expert, Molecular Partners' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Molecular Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Molecular. Basic forecasting techniques help filter out the noise by identifying Molecular Partners' price trends.Molecular Partners Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Molecular Partners stock to make a market-neutral strategy. Peer analysis of Molecular Partners could also be used in its relative valuation, which is a method of valuing Molecular Partners by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Molecular Partners Market Strength Events
Market strength indicators help investors to evaluate how Molecular Partners stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Molecular Partners shares will generate the highest return on investment. By undertsting and applying Molecular Partners stock market strength indicators, traders can identify Molecular Partners AG entry and exit signals to maximize returns.
| Accumulation Distribution | 818.12 | |||
| Daily Balance Of Power | 0.6 | |||
| Rate Of Daily Change | 1.05 | |||
| Day Median Price | 4.58 | |||
| Day Typical Price | 4.59 | |||
| Price Action Indicator | 0.14 | |||
| Period Momentum Indicator | 0.21 |
Molecular Partners Risk Indicators
The analysis of Molecular Partners' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Molecular Partners' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting molecular stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 2.97 | |||
| Semi Deviation | 3.26 | |||
| Standard Deviation | 4.13 | |||
| Variance | 17.1 | |||
| Downside Variance | 13.01 | |||
| Semi Variance | 10.64 | |||
| Expected Short fall | (3.50) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Molecular Partners
The number of cover stories for Molecular Partners depends on current market conditions and Molecular Partners' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Molecular Partners is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Molecular Partners' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Molecular Partners Short Properties
Molecular Partners' future price predictability will typically decrease when Molecular Partners' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Molecular Partners AG often depends not only on the future outlook of the potential Molecular Partners' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Molecular Partners' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 34 M | |
| Cash And Short Term Investments | 149.4 M |
Check out Historical Fundamental Analysis of Molecular Partners to cross-verify your projections. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Will Biotechnology sector continue expanding? Could Molecular diversify its offerings? Factors like these will boost the valuation of Molecular Partners. Expected growth trajectory for Molecular significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Molecular Partners data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Molecular Partners' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Molecular Partners represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Molecular Partners' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.